

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: USA3960 US CNT

INVENTORS: BORCHERDING, et al.

TITLE: ACYL AND SULFONYL DERIVATIVES
OF 6,9-DISUBSTITUTED 2-(TRANS-1,4-
DIAMINOCYCLOHEXYL)-PURINES AND THEIR USE
AS ANTIPIROLIFERATIVE AGENTS

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to Mail Stop
Patent Application, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450, on

October 2, 2003

Date of Deposit

Jens Pierce, Sr.

Signature

EL 964841904 US

Express Mail No.

31109 U.S.PTO
10/677683

100203

APPLICATION ELEMENTS

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification Total Pages 219
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages 4
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR § 1.63(d))
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Power of Attorney Total Pages
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR § 1.63(d))
6. Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- Computer Readable Copy
 - Paper Copy (identical to computer copy)
 - Statement verifying identity of above copies

If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part

of prior application no: 09/998,976, filed October 31, 2001.

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/244,567, filed October 31, 2000. (The cross reference has been/will be inserted on page one of the specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. Assignment Papers (cover sheet & document(s))
8. 37 CFR §3.73(b) Statement
(when there is an assignee)
9. Verified English Translation Document *(if applicable)*
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. Other: Application Data Sheet

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


Michael Schmelzer, Reg. No. 43,093

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4797
Telefax (908) 231-2626
Aventis Docket No. USA3960 US CNT